ATE554758T1 - Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs - Google Patents

Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs

Info

Publication number
ATE554758T1
ATE554758T1 AT05724487T AT05724487T ATE554758T1 AT E554758 T1 ATE554758 T1 AT E554758T1 AT 05724487 T AT05724487 T AT 05724487T AT 05724487 T AT05724487 T AT 05724487T AT E554758 T1 ATE554758 T1 AT E554758T1
Authority
AT
Austria
Prior art keywords
triptolide
lactone ring
cancer agent
immune modulators
ring derivatives
Prior art date
Application number
AT05724487T
Other languages
German (de)
English (en)
Inventor
Hongwei Yuan
John Musser
Dongcheng Dai
Original Assignee
Pharmagenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagenesis Inc filed Critical Pharmagenesis Inc
Application granted granted Critical
Publication of ATE554758T1 publication Critical patent/ATE554758T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT05724487T 2004-03-02 2005-03-02 Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs ATE554758T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54976904P 2004-03-02 2004-03-02
PCT/US2005/006952 WO2005084365A2 (en) 2004-03-02 2005-03-02 Triptolide lactone ring derivatives as immunomodulators and anticancer agents

Publications (1)

Publication Number Publication Date
ATE554758T1 true ATE554758T1 (de) 2012-05-15

Family

ID=34919536

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05724487T ATE554758T1 (de) 2004-03-02 2005-03-02 Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs

Country Status (10)

Country Link
US (2) US7863464B2 (OSRAM)
EP (1) EP1732536B1 (OSRAM)
JP (1) JP5057966B2 (OSRAM)
CN (1) CN100558354C (OSRAM)
AT (1) ATE554758T1 (OSRAM)
AU (1) AU2005218610B2 (OSRAM)
CA (1) CA2557260C (OSRAM)
DK (1) DK1732536T3 (OSRAM)
ES (1) ES2385716T3 (OSRAM)
WO (1) WO2005084365A2 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7847109B2 (en) * 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
WO2005062913A2 (en) * 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
US8048914B2 (en) 2004-02-09 2011-11-01 Pharmagenesis, Inc. Methods for isolation of triptolide compounds from Tripterygium wilfordii
US7863464B2 (en) 2004-03-02 2011-01-04 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
US8617906B2 (en) * 2004-10-13 2013-12-31 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
US8268882B2 (en) 2009-02-05 2012-09-18 Pharmagenesis, Inc. Triptolide C-ring derivatives as anticancer agents and immune modulators
PL2427467T3 (pl) 2009-05-07 2016-04-29 Univ Minnesota Proleki tryptolidu
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
WO2014145303A1 (en) * 2013-03-15 2014-09-18 Pharmagenesis, Inc. Intravenous emulsions of triptolide as immunomodulators and anticancer agents i
WO2015127011A1 (en) 2014-02-21 2015-08-27 Institute Of Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center C-myc as a biomarker for tumor sensitivity to treatment with rna polymerase ii inhibition
WO2016181312A1 (en) * 2015-05-11 2016-11-17 Versitech Limited Polycyclic epoxides and compositions thereof with anti-cancer activities
CN107663225A (zh) * 2016-07-29 2018-02-06 欣凯医药化工中间体（上海）有限公司 一种氟代雷公藤内酯醇内酯环衍生物
CN106749496A (zh) * 2016-12-05 2017-05-31 张奇军 新型雷公藤甲素衍生物、及其制备和用途
CN108530510A (zh) * 2017-03-02 2018-09-14 欣凯医药化工中间体（上海）有限公司 一种c19-酰基化雷公藤甲素的制备方法
CN108530511B (zh) * 2017-03-02 2021-06-22 欣凯医药化工中间体（上海）有限公司 一种c19-酰基化雷公藤甲素衍生物
WO2018222351A1 (en) * 2017-05-27 2018-12-06 Pharmagenesis, Inc. Triptolide lactone derivatives as immunomodulators and anticancer agents
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体（上海）有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN110551171B (zh) * 2018-05-31 2021-07-27 欣凯医药化工中间体（上海）有限公司 一种雷公藤内酯醇衍生物的制备方法
CN110551170B (zh) * 2018-05-31 2022-04-22 欣凯医药化工中间体（上海）有限公司 一种c-19位单酰基化雷公藤内酯醇衍生物的合成方法
CN110551172B (zh) * 2018-05-31 2021-08-27 欣凯医药化工中间体（上海）有限公司 一种c-19位双键化雷公藤内酯醇衍生物的合成方法
CN111909119B (zh) * 2020-08-25 2023-06-16 上海诗丹德标准技术服务有限公司 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005108A (en) 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
CA1310009C (en) 1984-03-28 1992-11-10 John Mark Braughler Ester prodrugs of steroids
CN1027371C (zh) 1989-09-08 1995-01-11 中国医学科学院皮肤病研究所 二萜内酯化合物的合成方法
CN1052859A (zh) 1989-12-22 1991-07-10 中国医学科学院皮肤病研究所 17-羟基雷藤内酯醇及类似物的结构与制备方法
US5430054A (en) 1989-12-22 1995-07-04 Jiangsu Family Planning Institute Preparation methods of diterpene lactone compounds and application of the same to antifertility
ES2069281T3 (es) 1990-03-06 1995-05-01 Otsuka Pharma Co Ltd Derivado de fenantreno.
US5580562A (en) 1990-03-14 1996-12-03 Board Of Regents The University Of Texas System Preparations and uses thereof for immunosuppression
AU7570191A (en) 1990-03-14 1991-10-10 Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5468772A (en) 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
US5759550A (en) 1993-05-06 1998-06-02 Pharmagenesis, Inc. Method for suppressing xenograft rejection
WO1994026265A1 (en) 1993-05-06 1994-11-24 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5648376A (en) 1995-01-19 1997-07-15 Pharmagenesis, Inc. Immunosuppressant diterpene compound
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5994064A (en) 1996-04-24 1999-11-30 Identigene, Inc. Simple and complex tandem repeats with DNA typing method
US6103875A (en) 1996-11-26 2000-08-15 Pharmagenesis, Inc. Antifungal compounds from pseudomonas viridiflava
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
HUP0003244A3 (en) 1997-05-23 2001-09-28 Aventis Pharmaceuticals Inc Br Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof
NZ500762A (en) 1997-05-23 2001-08-31 Aventis Pharma Inc Triptolide derivatives substituted with amino acids, useful in the treatment of autoimmune diseases
US6004999A (en) 1997-05-23 1999-12-21 Hoechst Marion Roussel, Inc. Triptolide derivatives useful in the treatment of autoimmune diseases
US5972998A (en) 1997-05-23 1999-10-26 Hoechst Marion Roussel, Inc. Triptolide derivatives useful in the treatment of autoimmune diseases
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
EP1109789B1 (en) 1998-09-02 2003-07-16 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
US6548537B1 (en) 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
US6329148B1 (en) 1999-02-16 2001-12-11 The Board Of Trustees Of The Leland Stanford University Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
WO2000063212A1 (en) 1999-04-16 2000-10-26 Chengdu Diao Pharmaceutical Group Company Limited Derivatives of triptolide, and preparation and uses thereof
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
CN1317248A (zh) 2000-04-13 2001-10-17 福建省医学科学研究所 紫雷藤杀虫剂及其制备方法
US20020077350A1 (en) 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2
WO2002017931A1 (fr) 2000-09-01 2002-03-07 Xiaomin Wang Utilisation d'un ou de plusieurs extraits de tripterygium wilfordii hook.f pour la preparation de medicaments destines a prevenir et a traiter des troubles du systeme nerveux
US6777441B2 (en) 2000-10-02 2004-08-17 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6620843B2 (en) 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
US6569893B2 (en) 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
US7847109B2 (en) 2002-05-31 2010-12-07 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
US20040018260A1 (en) 2002-06-19 2004-01-29 Novemed Group Limited Novel botanical extract of Tripterygium Wilfordii Hook F.
CN1726025A (zh) 2002-12-17 2006-01-25 泛华医药公司 作为免疫调节剂和抗癌剂的雷公藤内酯醇衍生物
US6943259B2 (en) 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005000291A1 (en) * 2003-06-27 2005-01-06 Pharmagenesis, Inc. Method for treatment of idiopathic pulmonary fibrosis using triptolide derivatives
WO2005062913A2 (en) 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
US8048914B2 (en) 2004-02-09 2011-11-01 Pharmagenesis, Inc. Methods for isolation of triptolide compounds from Tripterygium wilfordii
US7863464B2 (en) 2004-03-02 2011-01-04 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
WO2006012204A2 (en) 2004-06-25 2006-02-02 Pharmagenesis, Inc. Method for treatment of inflammatory disorders using triptolide compounds

Also Published As

Publication number Publication date
US8426616B2 (en) 2013-04-23
EP1732536B1 (en) 2012-04-25
WO2005084365A3 (en) 2005-11-10
ES2385716T3 (es) 2012-07-30
AU2005218610A1 (en) 2005-09-15
WO2005084365A2 (en) 2005-09-15
AU2005218610B2 (en) 2011-08-18
CA2557260C (en) 2013-02-12
JP2007526331A (ja) 2007-09-13
DK1732536T3 (da) 2012-06-25
CN1925852A (zh) 2007-03-07
US20080287530A1 (en) 2008-11-20
CN100558354C (zh) 2009-11-11
US7863464B2 (en) 2011-01-04
CA2557260A1 (en) 2005-09-15
US20100331554A1 (en) 2010-12-30
EP1732536A2 (en) 2006-12-20
JP5057966B2 (ja) 2012-10-24
EP1732536A4 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
ATE554758T1 (de) Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
CL2009000380A1 (es) Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras.
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
EP4305032A4 (en) 7-MORPHOLINO-1,6-NAPHTYRIDIN-5-YL DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS USEFUL AS DNA-PK INHIBITOR
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008003188A1 (es) Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met.
EP1824442A4 (en) PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FROM THE GARCINIA MANGOSTANA L PLANT
UY28736A1 (es) Derivados de quinazolina
WO2019118411A3 (en) Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
NO20090251L (no) Camptotecinderivater med antitumoraktivitet
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
TR200200821T2 (tr) 5-Beta-sapojenin ve pseudosapojenin türevleri ve bunların bunama tedavisinde kullanımı.
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
ATE389398T1 (de) Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
ATE388149T1 (de) Neue azaindol-thiazolinone als krebsmittel
WO2007076160A3 (en) C-10 carbamates of taxanes
DE602006002887D1 (de) Tricyclische azolderivate, ihre herstellung und ihre verwendung als pharmazeutische mittel
DE602005006653D1 (de) Differenzverstärker, zweistufiger Differenzverstärker und Analog-Digital-Wandler
WO2005090372A3 (en) Platinum carboxylate anticancer compounds
WO2010091193A3 (en) Triptolide c-ring derivatives as anticancer agents and immune modulators
MX2009009178A (es) Bis-fosforatos de bazedoxifeno.